2
Total investments
0
Early stage
1
Mid stage
0
Late stage
8y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member and CEO
Jun 2019
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
Experience · 5 entries
All (5)
Investments (2)
Founder (2)
Board (2)
2019
Board Member and CEO
Jun 2019
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
2018
A
Arrow Immune, Inc.
Board Member
Aug 2018
2016
D
Dornbusch & Company
Founder
Feb 2016
2014
B
Co-Founder and CEO
Aug 2014
BioGraph 55, Inc. is a San Francisco based early-stage target discovery and drug development biotech company focused on immuno-oncology. The company leverages a proprietary and scientifically validated (through external partners) spatial-mapping technology platform called SPARTA (Spatial Processing And Regional Tissue Analysis) that collects biological information from cellular interactions and integrates this information with genomic/transcriptomic data to identify novel drug targets. Our first program aims to develop an antibody therapy that: i) targets ~ 30-50% of nonresponsive, "hot" tumors, ii) targets a largely unexplored cell regulator of tumor immunity and iii) works by removing local immunosuppression from "hot" tumors.
1997
Associate Director, Business Development
Dec 1997
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.
We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms